TQB2102

Phase 3Small molecule

CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

TQB2102 is one of 61 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Breast CancerPhase 2

Active, not recruiting

Colorectal CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Halaven

Eisai

Preclinical

38 3

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 4

TQB2102

CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 3

3 5

DATROWAY

Daiichi Sankyo

Preclinical

4 6

Megace

Bristol-Myers Squibb

Preclinical

4 7

Voltaren

Novartis

Preclinical

1 8

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 9

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 10

Spravato

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Active, not recruiting

Advanced Cancers

NCT05735496

Q3 2028

Phase 2Recruiting

Breast Cancer

NCT05582499

Q4 2028

Phase 3Not yet recruiting

Colorectal Cancer

NCT07483684

Phase 3Recruiting

Breast Cancer

NCT07008976

Q3 2030

Phase 2Not yet recruiting

Breast Cancer

NCT07136974

Clinical

Trials by Indication[1]

Breast Cancer3 trials

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Recruiting·FFudan University·Phase 2·NCT05582499·716 enrolled

Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.

Not yet recruiting·HHenan Cancer Hospital·Phase 2·NCT07136974·280 enrolled

Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer

Recruiting·CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.·Phase 3·NCT07008976·246 enrolled

Colorectal Cancer1 trial

A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs

Not yet recruiting·CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.·Phase 3·NCT07483684·142 enrolled

Advanced Cancers1 trial

Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers

Active, not recruiting·CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.·Phase 1·NCT05735496·219 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for TQB2102. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TQB2102 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TQB2102. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

TQB2102

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2028

Q4 2028

Q3 2030

Trials by Indication[1]

Breast Cancer3 trials

Colorectal Cancer1 trial

Advanced Cancers1 trial

References

Drug Info

Quick Facts

Related News